Plasma Kallikrein Inhibition: A Novel Approach to DME

Arshad Khanani, MD, MA, FASRS

Show Description +

Dr. Khanani shares phase 2a data for RZ402 (Rezolute), an investigational oral therapy showing early promise for the treatment of diabetic macular edema.

Posted: 10/01/2024

Keywords:

RZ402

•

Rezolute

•

retina-meeting-recap

•

plasma kallikrein inhibition

•

Diabetic macular edema, DME

•

Clinical Trials

•

oral therapy

Up Next

Name: Plasma Kallikrein Inhibition: A Novel Approach to DME
Uploaded: 2024-10-01T22:14:40+00:00
Description: Dr. Khanani shares phase 2a data for RZ402 (Rezolute), an investigational oral therapy showing early promise for the treatment of diabetic macular edema.

Next-Gen Therapies for AMD and DME

Nicole Eter, MD

The Role of Anti-VEGF Therapy in Diabetic Vitreous Hemorrhage

David Steel, MD, MBBS, FRCOphth

Exploring VEGF-C and -D Inhibition

Timothy L. Jackson, PhD, MB ChB, FRCOphth

The Clinical Benefits of the PDS

Patricia Udaondo, MD

RD Repair: Why Slower Reattachment is Better

Stratos V. Gotzaridis, MBBS, MD

Today's Approaches to Myopic Neovascularization

Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI

Anti-VEGF for ROP: Efficacy and Safety Outcomes

Andreas Stahl, MD

Advancing Research Methodology in Retina

Varun Chaudhary, MD, FRCS(C)

The Clinical Challenges of AAV Vectors

Kanmin Xue, PhD, MA, MB, BChir, FRCOphth

Back to All Videos

Plasma Kallikrein Inhibition: A Novel Approach to DME

Arshad Khanani, MD, MA, FASRS

Dr. Khanani shares phase 2a data for RZ402 (Rezolute), an investigational oral therapy showing early promise for the treatment of diabetic macular edema.

Posted: 10/01/2024

Keywords:

RZ402

•

Rezolute

•

retina-meeting-recap

•

plasma kallikrein inhibition

•

Diabetic macular edema, DME

•

Clinical Trials

•

oral therapy

Please log in to leave a comment.

Meeting Coverage:

EURETINA Congress

Plasma Kallikrein Inhibition: A Novel Approach to DME

Up Next

Plasma Kallikrein Inhibition: A Novel Approach to DME

More From EURETINA: 2024 Coverage